Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

Thrombotic Microangiopathy Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger

Status Terminated

Clinical Trial Summary

This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04743804
Study type	Interventional
Source	Alexion Pharmaceuticals, Inc.
Contact
Status	Terminated
Phase	Phase 3
Start date	July 1, 2021
Completion date	December 22, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02604420` - Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Recruiting	`NCT04557735` - Study of Ravulizumab in Pediatric Participants With HSCT-TMA	Phase 3
Recruiting	`NCT04845022` - Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
Terminated	`NCT00593229` - International Registry and Biorepository for TMA(Thrombotic Microangiopathy)	N/A
Recruiting	`NCT05991245` - French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Terminated	`NCT00726544` - Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy	Phase 2
Recruiting	`NCT04543591` - Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant	Phase 3
Available	`NCT02355782` - OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy	N/A